Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 2:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 256 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Human Immunodeficiency Virus Exposure Clear all
Recruiting Not applicable Interventional

El Camino HIV Prevention and Care Study

NCT07834853
View directory record Official record
Conditions
HIV Infections
Interventions
Camino Intervention
Behavioral
Lead sponsor
American University
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Berkeley, California • Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 25, 2026, 2:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Supporting Tailored And Responsive PrEP in Rural North Carolina

NCT05984030
View directory record Official record
Conditions
HIV Pre-Exposure Prophylaxis
Interventions
PrEP Navigation Services, Telehealth PrEP Services Referral, HealthMpowerment Digital Health Intervention - Enhanced, HealthMpowerment Digital Health Intervention - Basic
Other · Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 39 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Sep 25, 2026, 2:15 AM EDT
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

Combatting HIV Or Other STIs Early (CHOOSE)

NCT07510048
View directory record Official record
Conditions
HIV, STIs, STIs Prevention, HIV Prevention
Interventions
Standard of care and PrEP Choice at Enrollment, Standard of care followed by PrEP Choice at Month 9
Other
Lead sponsor
Westat
Other
Eligibility
13 Years to 24 Years · Male only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
6
States / cities
San Francisco, California • Washington D.C., District of Columbia • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 25, 2026, 2:15 AM EDT
Not listed Not applicable Interventional

Linking Women to PrEP Care

NCT03281343
View directory record Official record
Conditions
Prevention
Interventions
Motivational Interviewing & Patient Navigator, Standard of Care (SOC)
Behavioral
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 4, 2023 · Synced Sep 25, 2026, 2:15 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety Study of a Dual Anti-HIV Gene Transfer Construct to Treat HIV-1 Infection

NCT01734850
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
Busulfan, Cal-1 modified HSPC, Cal-1 modified CD4+ T lymphocytes
Drug · Biological
Lead sponsor
Calimmune, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
Los Angeles, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 5, 2020 · Synced Sep 25, 2026, 2:15 AM EDT
Completed No phase listed Observational

Adherence, HIV-1 Infection, Resistance, and Renal and Skeletal Adverse Event in Individuals Taking Truvada® for HIV Pre-Exposure Prophylaxis (PrEP)

NCT01906255
View directory record Official record
Conditions
HIV
Interventions
Not listed
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
10,577 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Foster City, California
Source: ClinicalTrials.gov public record
Updated Aug 31, 2021 · Synced Sep 25, 2026, 2:15 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Safety Tolerability and Acceptability of Long Acting Injections of the Human Immunodeficiency Virus (HIV) Integrase Inhibitor, GSK1265744, in HIV Uninfected Men (ECLAIR)

NCT02076178
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
744 Tablet, 744 LA Injection, Placebo Tablet, Placebo Injection
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
127 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
10
States / cities
San Francisco, California • Washington D.C., District of Columbia • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2017 · Synced Sep 25, 2026, 2:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pre-Exposure Prophylaxis in the Emergency Department

NCT04429971
View directory record Official record
Conditions
HIV/AIDS, PrEP
Interventions
PrEP screening program, PrEP starter pack
Other
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Sep 25, 2026, 2:15 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Post-Exposure Prophylaxis in Health Care Workers

NCT01234116
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
emtricitabine/tenofovir disoproxil fumarate
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Sep 25, 2026, 2:15 AM EDT
Recruiting No phase listed Observational

Mobile Vehicle-Based Delivery of Lenacapavir Pre-Exposure Prophylaxis in Los Angeles County

NCT07467018
View directory record Official record
Conditions
HIV Prevention
Interventions
Community-based healthcare delivery, Lenacapavir
Other · Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Sep 25, 2026, 2:15 AM EDT
Withdrawn Not applicable Interventional

Treatment Plan to Decrease Drug Exposure in HIV Infected Adolescents

NCT00067574
View directory record Official record
Conditions
HIV Infections
Interventions
Structured treatment interruption
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
14 Years to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
4
States / cities
San Diego, California • Washington D.C., District of Columbia • Fort Lauderdale, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2017 · Synced Sep 25, 2026, 2:15 AM EDT
Completed Phase 1 Interventional Results available

Evaluating the Safety and Pharmacokinetics of Maraviroc in HIV-1-Exposed Infants at Risk of Acquiring HIV-1 Infection

NCT02778204
View directory record Official record
Conditions
HIV Infections
Interventions
Maraviroc
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 3 Days
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
5
States / cities
Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2022 · Synced Sep 25, 2026, 2:15 AM EDT
Completed Phase 3 Interventional Results available

Development of Ingestible Biosensors to Enhance PrEP Adherence in Substance Users (PrEPSteps)

NCT03512418
View directory record Official record
Conditions
HIV Infections, Substance Use Disorders
Interventions
PrEPsteps, Digital pill, Truvada
Behavioral · Device · Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Boylston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Sep 25, 2026, 2:15 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

HIV Exposure in Utero and Metabolic Disease Risk in HIV-Negative Young Adults

NCT04132830
View directory record Official record
Conditions
HIV-exposed Uninfected
Interventions
In Utero HIV Exposure, No In Utero HIV Exposure
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
174 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 22, 2024 · Synced Sep 25, 2026, 2:15 AM EDT
Recruiting No phase listed Observational

Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention

NCT07473778
View directory record Official record
Conditions
HIV Infections
Interventions
Lenacapavir Injection, Emtricitabine/tenofovir disoproxil fumarate (F/TDF), Emtricitabine/tenofovir alafenamide (F/TAF), Cabotegravir (CAB), Lenacapavir Tablet
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
3,000 participants
Timeline
2026 – 2029
U.S. locations
38
States / cities
Birmingham, Alabama • Beverly Hills, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 25, 2026, 2:15 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Evaluating The Acceptability and Uptake of Pre-Exposure Prophylaxis (PrEP) for Adolescent Women in The Deep South

NCT03897725
View directory record Official record
Conditions
Adolescent Behavior, HIV/AIDS, PrEP
Interventions
Telehealth Coaching
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
15 Years to 21 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Nov 11, 2021 · Synced Sep 25, 2026, 2:15 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Enhancing PrEP Uptake and Retention Among Latine TGW and GBM in the South Using Long-Acting Injectable PrEP

NCT07218211
View directory record Official record
Conditions
HIV Prevention, HIV Pre-exposure Prophylaxis, HIV Prevention Program, HIV Prevention and Care, HIV Pre-exposure Prophylaxis Use
Interventions
Lenacapavir long-acting
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Male only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 25, 2026, 2:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Adapting a Behavioral Intervention to Accommodate Cognitive Dysfunction in People Who Inject Drugs

NCT05912374
View directory record Official record
Conditions
Cognitive Dysfunction
Interventions
standard Community-Friendly Health Recovery Program- Biobehavioral (CHRP-BB), enhanced Community-Friendly Health Recovery Program- Biobehavioral (CHRP-BB)
Behavioral
Lead sponsor
University of Connecticut
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Sep 25, 2026, 2:15 AM EDT
Recruiting Not applicable Interventional

Pre-exposure Prophylaxis (PrEP) for Health

NCT04430257
View directory record Official record
Conditions
Substance Dependence, HIV (Human Immunodeficiency Virus)
Interventions
HIV and PrEP education, Motivational interviewing, Problem-solving and planning, Patient navigation, PrEP information, Referrals
Other · Behavioral
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Cambridge, Massachusetts • Lawrence, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 3, 2025 · Synced Sep 25, 2026, 2:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Development and Evaluation of a PrEP Decision Aid for Women Seeking Domestic Violence Services in Baltimore

NCT05614492
View directory record Official record
Conditions
HIV, Violence, Gender-Based, Pre-Exposure Prophylaxis
Interventions
Individual PrEP Decision Aid, CDC PrEP Video, Shared PrEP Decision Aid
Behavioral
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years and older · Female only
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced Sep 25, 2026, 2:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study of Zidovudine in the Prevention of HIV Infection in Individuals Exposed to the Virus

NCT00000993
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2005
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 6, 2016 · Synced Sep 25, 2026, 2:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Peer Outreach and Navigation Intervention to Increase PrEP Uptake Among Women at High Risk for HIV

NCT03226873
View directory record Official record
Conditions
Pre-exposure Prophylaxis, HIV-1-infection
Interventions
Peer Navigation
Behavioral
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 15, 2018 · Synced Sep 25, 2026, 2:15 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Pre-Exposure Prophylaxis and Timed Intercourse for HIV-Discordant Couples

NCT02572505
View directory record Official record
Conditions
HIV, Infertility
Interventions
Truvada
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years to 40 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Sep 25, 2026, 2:15 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103)

NCT06101342
View directory record Official record
Conditions
Pre-Exposure Prophylaxis of HIV Infection
Interventions
Lenacapavir Injection, Lenacapavir Tablet, Emtricitabine/tenofovir disoproxil fumarate (F/TDF)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
181 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
9
States / cities
Los Angeles, California • San Diego, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 25, 2026, 2:15 AM EDT